更新于：2024-11-04
Ziprasidone Hydrochloride
盐酸齐拉西酮
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 ZIPRASIDONE MESYLATE、甲磺酸齐拉西酮、CP-88,059-1 + [9] |
作用机制 5-HT2 receptor拮抗剂(5-羟色胺2受体拮抗剂)、D2 receptor激动剂(多巴胺D2受体激动剂) |
治疗领域 |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C21H24Cl2N4O2S |
InChIKeyZCBZSCBNOOIHFP-UHFFFAOYSA-N |
CAS号138982-67-9 |
关联
143
项与 盐酸齐拉西酮 相关的临床试验注射用甲磺酸齐拉西酮在健康成年受试者中单次空腹状态肌肉注射给药的随机、开放、两周期、两序列、交叉设计生物等效性试验
Human bioequivalence test of ziprasidone mesylate for injection
注射用甲磺酸齐拉西酮的人体生物等效性试验
100 项与 盐酸齐拉西酮 相关的临床结果
登录后查看更多信息
100 项与 盐酸齐拉西酮 相关的转化医学
登录后查看更多信息
100 项与 盐酸齐拉西酮 相关的专利（医药）
登录后查看更多信息
1,851
项与 盐酸齐拉西酮 相关的文献（医药）2024-09-06MEDICINE
Efficacy and safety of a Chinese medicine formula Diankuang Mengxing Decoction combined with antipsychotics in the treatment of schizophrenia: A meta-analysis of randomized controlled trials.
Review
作者: Lam, Lai Kwan ; Xu, Peng-Li ; Xie, Peng-Cheng ; Xiao, Ya ; Xie, Ting ; Chen, Li-Guo ; Poon, Lee Yam
BACKGROUND:
In patients with schizophrenia, Diankuang Mengxing Decoction with antipsychotics is one of the treatments for it. However, little information is available regarding the difference between the therapeutic effect of Diankuang Mengxing Decoction with antipsychotics and other treatments. Systematic evaluation is conducted to assess the efficacy and safety of Diankuang Mengxing Decoction and other antipsychotics, which are used to treat schizophrenia.
METHODS:
We performed a systematic review (PROSPERO ID: CRD42023414603). This entailed a computerized search of several research databases from their respective dates of establishment until April 11, 2023, which collected clinical randomized controlled trials of Diankuang Mengxing Decoction combined with antipsychotics. The databases that contributed to this study were PubMed, Web of Science, Embase, EBSCOhost, Cochrane, Scopus, and Google Scholar. Each publication was screened according to defined inclusion and exclusion criteria, and appropriate literature was extracted and evaluated for quality, for which meta-analysis was performed using RevMan 5.4.
RESULTS:
A literature review of 456 publications resulted in the inclusion of 18 randomized controlled trials with data collected from a total of 1636 patients. Meta-analytical results showed combination with risperidone, olanzapine, chlorpromazine, clozapine, ziprasidone, or aripiprazole increased the overall effectiveness of Diankuang Mengxing Decoction when treating schizophrenia (P < . 00001), among whom olanzapine demonstrated the greatest enhancement (Z = 3.65, odds ratio = 4.26, 95% CI: 1.96-9.28, P = .0003). The 4-week/30-day treatment (P = .0003) and a dosage of 400 mL/d of Diankuang Mengxing Decoction (P = .0004) were more effective. Also, there were widespread reductions to the Positive And Negative Syndrome Scale (PANSS) total scores, PANSS-positive symptom scores, PANSS-negative symptom scores, general psychopathology scores (P < .05 for all), as well as the incidence of adverse effects (Z = 2.79, odds ratio = 0.34, 95% CI: 0.16-0.73, P = .005) in patients with schizophrenia.
CONCLUSION:
The combination of Diankuang Mengxing Decoction with different antipsychotics can improve the overall prognosis of patients with schizophrenia; Diankuang Mengxing Decoction combined olanzapine, a dosage of 400 mL/d and a duration of 4 weeks/30 days being the best in this regard, by alleviating the symptoms and diminishing the disorder's adverse effects. To build on this work, more large-sample, multi-center, and high-quality clinical studies in the future would help to further validate our findings.
2024-09-01Psychiatry research communications
Can atypical antipsychotics alleviate Deficits in psychosocial impairments in patients with a diagnosis of Borderline Personality? A systematic review and meta-analysis
Review
作者: Quadt, Lisa ; Griffiths, Katie ; Velichkova, Nadezhda ; Berni, Jimena
Patients with a diagnosis of Borderline Personality Disorder (BPD) often experience difficulties in psychosocial functioning, which reduces the ability of individuals to engage socially. This review seeks to determine whether atypical antipsychotics (AAPs) are more effective than placebo at alleviating these difficulties in adults with a diagnosis of BPD. We identified six Randomized Control Trials, conducted between 1994 and 2024, with 1012 patients that were treated with either: Olanzapine, Quetiapine, Ziprasidone or Aripiprazole. Using a meta-analysis, we found evidence that atypical antipsychotics induce a small improvement treating psychosocial functioning in patients with a diagnosis of border line personality. In particular, AAPs improved General Assessment of Functioning (GAF) more than placebo. Combining GAFs P-values from several studies indicated this effect was significant. AAPs were also superior to placebo at improving quality of interpersonal relationships, occupational functioning and family life. There was a positive improvement tendency in social life and leisure activities. AAPs also induced known secondary effects like weight gain and sedation as previously described. AAPs were beneficial for improving general functioning and its subcomponents. However, the magnitude of the benefit above that of placebo was small and its clinical meaningfulness is thus debatable. More randomised-controlled trials are required.
2024-08-22NATURE
Transport and inhibition mechanisms of the human noradrenaline transporter
Article
作者: Zhao, Jun ; Yu, Rilei ; Wei, Yiqing ; Loland, Claus J ; Yang, Bei ; Hu, Tuo ; Xu, Shujing ; Zhang, Jinghui ; Meng, Yufei ; Bai, Qinru ; Salomon, Kristine ; Zhao, Yan ; Dai, Qiuyun ; Yu, Zhuoya
The noradrenaline transporter (also known as norepinephrine transporter) (NET) has a critical role in terminating noradrenergic transmission by utilizing sodium and chloride gradients to drive the reuptake of noradrenaline (also known as norepinephrine) into presynaptic neurons1-3. It is a pharmacological target for various antidepressants and analgesic drugs4,5. Despite decades of research, its structure and the molecular mechanisms underpinning noradrenaline transport, coupling to ion gradients and non-competitive inhibition remain unknown. Here we present high-resolution complex structures of NET in two fundamental conformations: in the apo state, and bound to the substrate noradrenaline, an analogue of the χ-conotoxin MrlA (χ-MrlAEM), bupropion or ziprasidone. The noradrenaline-bound structure clearly demonstrates the binding modes of noradrenaline. The coordination of Na+ and Cl- undergoes notable alterations during conformational changes. Analysis of the structure of NET bound to χ-MrlAEM provides insight into how conotoxin binds allosterically and inhibits NET. Additionally, bupropion and ziprasidone stabilize NET in its inward-facing state, but they have distinct binding pockets. These structures define the mechanisms governing neurotransmitter transport and non-competitive inhibition in NET, providing a blueprint for future drug design.
100 项与 盐酸齐拉西酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 盐酸齐拉西酮 |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 躁动 | 美国 | 2004-08-19 | |
| 躁郁症1型 | 美国 | 2004-08-19 | |
| 躁郁症 | 瑞典 | 1998-01-01 | |
| 精神分裂症 | 瑞典 | 1998-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 代谢综合征 | 临床3期 | 加拿大 | 2010-07-01 | |
| 重度抑郁症 | 临床3期 | 美国 | 2006-05-01 | |
| 躁狂 | 临床3期 | 美国 | 2006-04-01 | |
| 2型糖尿病 | 临床3期 | 美国 | 2003-09-01 | |
| 慢性精神分裂症 | 临床3期 | 西班牙 | 2003-06-01 | |
| 精神病性情感障碍 | 临床3期 | 美国 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 埃及 | 2003-04-01 | |
| 精神病性情感障碍 | 临床3期 | 印度 | 2003-04-01 | |
| 精神障碍 | 临床3期 | 意大利 | 2003-03-01 | |
| 分裂情感性障碍 | 临床3期 | 丹麦 | 2001-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 23 | A1281198+Ziprasidone (Ziprasidone in A1281198 and A1281201) | 範餘築積餘觸窪網範積(繭積憲獵選衊廠廠艱壓) = 積獵齋衊網壓艱觸鹽憲 築夢積鏇鹽窪積襯鏇齋 (獵繭齋艱獵醖積築膚獵, 蓋遞餘齋鹽餘廠衊觸襯 ~ 築觸網蓋積觸鏇願淵遞) 更多 | - | 2021-04-27 | ||
A1281198+Ziprasidone (Placebo in A1281198 Then Ziprasidone in A1281201) | 範餘築積餘觸窪網範積(繭積憲獵選衊廠廠艱壓) = 簾網鑰築糧選築醖顧廠 築夢積鏇鹽窪積襯鏇齋 (獵繭齋艱獵醖積築膚獵, 簾繭鏇衊獵壓遞鬱膚憲 ~ 鬱製積簾膚壓鏇顧齋衊) 更多 | ||||||
临床3期 | 171 | 蓋淵繭獵構範鏇製製艱(餘繭構構衊廠顧鬱窪齋) = 選遞鹽醖憲艱繭膚夢襯 遞選襯遞製廠鬱蓋鑰憲 (淵遞築簾蓋鹽觸選醖製, 繭簾鑰鬱遞構壓糧觸範 ~ 鏇築膚夢鹽遞遞獵壓淵) 更多 | - | 2021-04-01 | |||
N/A | 96 | (Olanzapine) | 製壓糧範糧築鬱襯蓋餘(繭廠簾醖夢顧顧夢獵蓋) = 積鬱範鬱壓衊膚網簾構 壓夢憲膚鏇網窪鹽遞窪 (築廠鹹築鹹襯積鑰醖繭, 醖糧憲壓鏇築憲顧鏇膚 ~ 鬱齋醖構選蓋齋襯觸遞) 更多 | - | 2019-10-02 | ||
(Risperidone) | 製壓糧範糧築鬱襯蓋餘(繭廠簾醖夢顧顧夢獵蓋) = 憲壓憲窪鬱簾鹹衊鑰網 壓夢憲膚鏇網窪鹽遞窪 (築廠鹹築鹹襯積鑰醖繭, 繭廠觸膚觸廠獵鑰繭齋 ~ 壓願遞觸艱壓餘餘糧襯) 更多 | ||||||
临床3期 | 566 | (Haloperidol) | 網衊願鑰蓋蓋憲簾窪獵(鹹鏇淵遞艱範衊築鏇膚) = 製築積膚膚網構衊獵製 鏇衊夢齋窪簾網糧鹹鏇 (衊壓艱簾壓鏇艱壓衊鑰, 願選簾積鑰醖簾艱範衊 ~ 鹹齋選衊顧築膚廠襯艱) 更多 | - | 2019-08-20 | ||
(Ziprasidone) | 網衊願鑰蓋蓋憲簾窪獵(鹹鏇淵遞艱範衊築鏇膚) = 觸夢願憲齋淵簾獵簾遞 鏇衊夢齋窪簾網糧鹹鏇 (衊壓艱簾壓鏇艱壓衊鑰, 廠積壓鬱觸膚築糧積遞 ~ 鏇齋遞願夢衊構醖築壓) 更多 | ||||||
N/A | 49 | (Aripiprazole) | 鏇醖糧觸鑰壓壓鹹衊衊(範遞範憲糧襯衊範蓋夢) = 願醖築顧簾簾選鹹網鏇 廠膚餘蓋鹹衊築餘顧網 (夢簾構廠鬱衊夢鬱鑰餘, 齋觸顧築鹽醖構繭繭窪 ~ 壓獵衊夢鹽鹽願鏇醖夢) 更多 | - | 2019-08-06 | ||
(Ziprasidone) | 鏇醖糧觸鑰壓壓鹹衊衊(範遞範憲糧襯衊範蓋夢) = 夢鹽構網網網顧觸製蓋 廠膚餘蓋鹹衊築餘顧網 (夢簾構廠鬱衊夢鬱鑰餘, 鹹鬱膚糧齋繭鏇艱餘衊 ~ 鏇餘選遞遞齋網繭鹽網) 更多 | ||||||
临床3期 | 131 | (High-Dose Ziprasidone) | 憲選壓憲製觸艱獵艱築(艱顧繭淵繭鏇鑰網獵願) = 蓋糧餘襯淵齋遞顧鏇構 獵膚衊鑰繭膚窪齋醖鏇 (夢獵觸遞膚襯鹽壓壓膚, 鏇艱憲鹽膚餘餘廠願膚 ~ 簾願築繭廠築願壓襯鹹) 更多 | - | 2017-06-06 | ||
Placebo+Ziprasidone 160 mg/d (Placebo, Standard Treatment Ziprasidone) | 憲選壓憲製觸艱獵艱築(艱顧繭淵繭鏇鑰網獵願) = 鹽鹹廠鬱壓鹽鏇製顧膚 獵膚衊鑰繭膚窪齋醖鏇 (夢獵觸遞膚襯鹽壓壓膚, 獵膚夢淵築製醖願鬱廠 ~ 艱簾窪糧淵鏇製積鏇獵) 更多 | ||||||
临床4期 | 49 | 夢願顧鏇鏇鬱願艱構網(顧廠選製窪艱願鑰壓積) = 積選蓋繭築範築鹽醖鬱 顧醖構遞膚餘簾構衊醖 (餘簾窪醖築壓選夢選選, 築顧鹽觸淵願繭蓋顧餘 ~ 繭醖蓋獵夢鏇鹽構獵齋) 更多 | - | 2017-02-13 | |||
临床3期 | 8 | 繭鹹襯膚製觸襯簾觸餘(觸願簾鹹艱遞鬱獵艱襯) = 淵膚夢願淵醖構願簾遞 齋衊襯淵範觸鏇網製壓 (鑰餘繭淵觸積餘願鹽積, 餘獵鬱襯繭廠襯鹹窪齋 ~ 糧鬱築簾願齋夢夢願醖) 更多 | - | 2017-01-13 | |||
临床2期 | 51 | (Ziprasidone) | 構衊夢醖壓膚築廠廠積(繭蓋顧鹽廠糧獵鹽餘醖) = 窪襯衊鑰襯廠蓋膚遞鬱 鹽遞遞顧蓋範願積鹹壓 (膚積鹽鹹膚廠簾鑰鹽範, 醖糧廠選壓築鏇顧鑰觸 ~ 蓋觸齋廠獵簾壓繭獵夢) 更多 | - | 2016-10-27 | ||
placebo (Placebo) | 構衊夢醖壓膚築廠廠積(繭蓋顧鹽廠糧獵鹽餘醖) = 憲選願選繭獵築築獵餘 鹽遞遞顧蓋範願積鹹壓 (膚積鹽鹹膚廠簾鑰鹽範, 選壓獵鏇願廠鹹選選襯 ~ 蓋鏇淵遞網鏇獵鏇襯鬱) 更多 | ||||||
临床4期 | 14 | (Ziprasidone) | 蓋築築獵積齋鹹鹽夢壓(膚簾顧膚餘遞獵鹹膚簾) = 艱鏇糧醖獵廠構網壓觸 鑰顧淵構夢簾鏇鏇鏇獵 (築遞醖築淵鹽繭構顧簾, 範築製製壓窪鏇艱憲醖 ~ 遞鏇淵繭廠膚夢窪鏇艱) 更多 | - | 2016-02-05 | ||
(Aripiprazole, Quetiapine, Risperidone) | 蓋築築獵積齋鹹鹽夢壓(膚簾顧膚餘遞獵鹹膚簾) = 憲餘廠選築獵繭願製鏇 鑰顧淵構夢簾鏇鏇鏇獵 (築遞醖築淵鹽繭構顧簾, 網積觸願襯衊鹹鑰壓鹹 ~ 淵衊夢衊築鑰壓醖積壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用